Immunotherapy for lung adenocarcinoma patients with bone metastases: who really needs it
Zhangheng Huang, Yuexin Tong, Lujian Zhu, Binbin Yang, Kai Chen, Peiling Dai · 2024
Read Immunotherapy for lung adenocarcinoma patients with bone metastases: who really needs it by Zhangheng Huang, Yuexin Tong, Lujian Zhu, Binbin Yang, Kai Chen, Peiling Dai (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11671745.txt.
Description
Zhangheng Huang and co-authors ask who gains from immunotherapy when lung cancer spreads to bone in a 2024 study. Bone spread is common at first diagnosis in lung adenocarcinoma. Immune drugs help some patients a lot and others barely at all. A tool to tell them apart would spare cost and harm.
The multicenter study drew over twenty thousand patients. About twelve thousand got immunotherapy. Matching balanced the groups for fair survival comparison. Treated patients lived longer overall. A risk model built from the data then sorted patients into subgroups. Benefit pooled in set risk bands. The tool aims to target immune therapy to those who truly need it.
Catalog record
| CREATOR | Zhangheng Huang, Yuexin Tong, Lujian Zhu, Binbin Yang, Kai Chen, Peiling Dai |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |